CytomX Therapeutics (CTMX) Operating Income (2016 - 2025)
Historic Operating Income for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$15.8 million.
- CytomX Therapeutics' Operating Income fell 48355.63% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year increase of 24643.82%. This contributed to the annual value of $25.0 million for FY2024, which is 48548.74% up from last year.
- Per CytomX Therapeutics' latest filing, its Operating Income stood at -$15.8 million for Q3 2025, which was down 48355.63% from -$1.3 million recorded in Q2 2025.
- CytomX Therapeutics' 5-year Operating Income high stood at $22.6 million for Q1 2025, and its period low was -$34.9 million during Q4 2021.
- For the 5-year period, CytomX Therapeutics' Operating Income averaged around -$10.2 million, with its median value being -$8.5 million (2024).
- Per our database at Business Quant, CytomX Therapeutics' Operating Income skyrocketed by 301732.67% in 2024 and then tumbled by 48355.63% in 2025.
- Over the past 5 years, CytomX Therapeutics' Operating Income (Quarter) stood at -$34.9 million in 2021, then surged by 72.76% to -$9.5 million in 2022, then surged by 93.63% to -$606000.0 in 2023, then surged by 3017.33% to $17.7 million in 2024, then crashed by 189.19% to -$15.8 million in 2025.
- Its last three reported values are -$15.8 million in Q3 2025, -$1.3 million for Q2 2025, and $22.6 million during Q1 2025.